Sign In
Buy STOK
$29.46
+0.780 (+2.72%)
At Close: Jun 03, 2026
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
04:01pm, Thursday, 28'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
12:27pm, Thursday, 21'st May 2026
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Monday, 18'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Q1 Earnings Call Highlights
12:09am, Saturday, 09'th May 2026
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
02:21am, Friday, 08'th May 2026
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
08:12pm, Thursday, 07'th May 2026
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
04:01pm, Thursday, 07'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
04:39pm, Friday, 01'st May 2026
I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a roll
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Thursday, 16'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
04:01pm, Wednesday, 08'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
04:01pm, Tuesday, 07'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
08:32pm, Friday, 27'th Mar 2026
The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026. The sale represented 12.20% of Tzianabos' direct Common Stock holdings
Assenagon Asset Management S.A. Boosts Position in Stoke Therapeutics, Inc. $STOK
03:07am, Thursday, 26'th Mar 2026
Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 36.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
12:35pm, Tuesday, 24'th Mar 2026
The chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026. This sale represented 26.01% of Tich
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
05:12pm, Tuesday, 17'th Mar 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
